Cowen sees hope for ECYT amid acquisition refocus; H.C.
It’s a very rewarding trading day for investors in Endocyte, Inc. (NASDAQ:ECYT) with shares up nearly 90%, making the stock Wall Street’s bull …
In a research report released Friday, Cowen analyst Boris Peaker downgraded shares of Endocyte, Inc. (NASDAQ:ECYT) from Outperform to Market Perform, after the drug maker …
Endocyte, Inc. (NASDAQ:ECYT) announced updates on clinical development for EC1456, its folate receptor-targeted tubulysin cancer therapy, and EC1169, its prostate-specific membrane antigen targeted …
Endocyte, Inc. (NASDAQ:ECYT) announced their plan to collaborate with Seattle Children’s Research Institute and Dr.
Endocyte, Inc. (NASDAQ:ECYT) presented poster updates on its two lead clinical programs at the ESMO 2016 Congress, being held in Copenhagen, Denmark October 7-11, …
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Mike …
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results …
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced in a …
In a research report published today, Cantor analyst Daniel Brims reiterated a Buy rating on shares of Endocyte, Inc. (NASDAQ:ECYT) with a price target …
